BiomX (PHGE) Depreciation & Amortization (CF) (2019 - 2025)
BiomX (PHGE) posted Depreciation & Amortization (CF) of $1.2 million for Q4 2025, up 192.91% sequentially from -$1.2 million in Q3 2025, and up 25.19% YoY from $921000.0 in Q4 2024.
BiomX (PHGE) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends
BiomX has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $1.2 million in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 25.19% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $204000.0 (down 88.73% YoY) and the FY2025 annual result came in at $2.9 million, up 62.06% from the prior year.
- Depreciation & Amortization (CF) advanced to $1.2 million in Q4 2025 per PHGE's latest filing, from -$1.2 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.2 million in Q4 2025 and troughed at -$1.2 million in Q3 2025.
- A 5-year average of $336368.4 and a median of $331000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 334.43% in 2024, then plunged 485.4% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at -$760000.0 in 2021, then surged by 182.11% to $624000.0 in 2022, then tumbled by 66.03% to $212000.0 in 2023, then jumped by 334.43% to $921000.0 in 2024, then climbed by 25.19% to $1.2 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.2 million, -$1.2 million, and $292000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BiomX | 351,774.34 | -816,225.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.15 Mn |
| Dec 31, 2025 | 1.15 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 292,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Dec 31, 2024 | 921,000.00 |
| Dec 31, 2024 | 921,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Sep 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Jun 30, 2024 | 331,000.00 |
| Dec 31, 2023 | 212,000.00 |
| Dec 31, 2023 | 212,000.00 |
| Sep 30, 2023 | 219,000.00 |
| Sep 30, 2023 | 219,000.00 |
| Jun 30, 2023 | 217,000.00 |
| Jun 30, 2023 | 217,000.00 |